Regencell Bioscience Holdings Ltd
corporate_fare Company Profile
Regencell Bioscience Holdings Ltd (NASDAQ:RGC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for RGC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-05-21, rated 8/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for RGC spans 424B5, 6-K.
Recent high-impact activity:
- Regencell Bioscience Hit With Class Action Lawsuit Alleging Market Manipulation, DOJ Probe
- Regencell Bioscience Finalizes $20M Direct Offering at 27% Discount
- Regencell Bioscience Finalizes $20M Direct Offering at 25% Discount with Institutional Investor
- Regencell Bioscience Secures $20M in Deeply Discounted Offering
- Regencell Bioscience Reports Deepening Losses, Going Concern Doubt, and Ongoing DOJ Investigation
Financial Snapshot
Short Interest & Short Volume
3.08 days to coverFINRA reported short interest of 801,244 shares in RGC as of the September 15, 2026 settlement, a 15.8% decrease from the prior period — about 3.1 days to cover at its recent average daily volume. On October 2, 2026, 57.2% of RGC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for RGC, detected from its recent SEC filings · based on capital-structure filings through 2026-05-19.
Registered Direct Offering Finalized · Significant Discount to Market Price
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
RGC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.